Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.
Saenger Y, Magidson J, Liaw B, Wassmann K, Barker W, Harcharik S, Fisher D, Oh W, Friedlander P. Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab. Journal Of Clinical Oncology 2013, 31: 9080-9080. DOI: 10.1200/jco.2013.31.15_suppl.9080.Peer-Reviewed Original ResearchPredictive of survivalInterleukin-1 receptor-associated kinase 3CTLA-4Training cohortValidation cohortPredicting SurvivalMulti-center phase II studyAntibody targeting CTLA-4Median time of followT-cell inhibitory moleculesMRNA signatureCTLA-4 blockadeRisk scorePhase II studyPhase III studyMultivariate Cox analysisMinority of patientsPeripheral blood samplesMulti-center phase III studyTime of followStage of diseaseHigh-risk groupLevels of cathepsin DCathepsin DACTLA-4
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply